Abstract
Major depressive disorders (MDDs) are often associated with a deficiency in long-chain omega-3 polyunsaturated fatty acids (ω-3 PUFAs), as well as signs of low-grade inflammation. Epidemiological and dietary studies suggest that a high intake of fish, the major source of ω-3 PUFAs, is associated with lower rates of MDDs. Meta-analyses of randomized placebo-controlled ω-3 PUFAs intervention-trials suggest that primarily eicosapentaenoic acid (EPA), but not docosahexaenoic acid (DHA), is responsible for the proposed antidepressant effect. In this review, we dissect the current biological knowledge on EPA and DHA and their bioactive lipid metabolites to search for a pharmacological explanation of this, to date, unexplained clinical observation. Through enzymatic conversion by cyclooxygenase (COX), lipoxygenase (ALOX), and cytochrome P-450 monooxygenase (CYP), EPA and DHA are metabolized to major anti-inflammatory and pro-resolving lipid mediators. In addition, both ω-3 PUFAs are precursors for endocannabinoids, with known effects on immunomodulation, neuroinflammation, food intake and mood. Finally, both ω-3 PUFAs are crucial for the structure and organization of membranes and lipid rafts. While most biological effects are shared by these two ω-3 PUFAs, some distinct features could be identified: (1) The preferential CYP monooxygenase pathway for EPA and EPA derived eicosanoids; (2) The high CB2 receptor affinities of EPA-derived EPEA and its epoxy-metabolite 17,18-EEQ-EA, while the DHA-derived endocannabinoids lack such receptor affinities; (3) The competition of EPA but not DHA with arachidonic acid (AA) for particular glycerophospholipids. EPA and AA are preferentially incorporated into phosphatidylinositols, while DHA is mainly incorporated into phosphatidyl-ethanolamine, -serine and -choline. We propose that these distinct features may explain the superior antidepressant activity of EPA rich ω-3 PUFAs and that these are potential novel targets for future antidepressant drugs.
Highlights
Epidemiological studies report an inverse association between intake of oily fish and the prevalence [1,2,3,4,5,6] and incidence of major depressive disorders (MDDs)* [7,8,9]
Lower levels of ω-3 PUFAs lead to increased ω-6/ω-3 ratios frequently reported in adult MDD [16,17,18,19], as well as in drug-naive pediatric MDD [20]
The epidemiological inverse association between fish intake and depression, as well as the observation of low ω-3 PUFAs in erythrocyte membranes of patients with MDD, triggered a range of ω-3 PUFAs intervention trials. Most of these studies were of a small scale; in most of these randomized placebo-controlled trials (RCTs) a beneficial effect of ω-3 PUFAs on depressive symptoms was corroborated across the lifespan
Summary
Epidemiological studies report an inverse association between intake of oily fish and the prevalence [1,2,3,4,5,6] and incidence of major depressive disorders (MDDs)* [7,8,9]. The epidemiological inverse association between fish intake and depression, as well as the observation of low ω-3 PUFAs in erythrocyte membranes of patients with MDD, triggered a range of ω-3 PUFAs intervention trials Most of these studies were of a small scale; in most of these randomized placebo-controlled trials (RCTs) a beneficial effect of ω-3 PUFAs on depressive symptoms was corroborated across the lifespan. Two RCTs in conditions with chronic inflammation and depression demonstrated a protective effect of ω-3 PUFAs against the development of depressive symptoms, which correlated with a decrease in pro-inflammatory mediators [109,110] These associations of reduced inflammation with better clinical outcome were further substantiated by an RCT showing that MDD patients with higher levels of inflammatory markers benefitted more from ω-3 PUFAs, than patients with no signs of low-grade inflammation [33]. While both ω-3 PUFAs inhibit the conversion of AA to the mainly pro-inflammatory eicosanoids, only EPA gives rise to metabolites, which are weak agonists at certain receptors that mediate pro-inflammatory responses of AA derived 2-series prostaglandins and 4-series leukotrienes [115]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have